David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Business Ethics Quarterly 15 (4):549-575 (2005)
The pharmaceutical industry has in recent years come under attack from an ethical point of view concerning its patents and thenon-accessibility of life-saving drugs for many of the poor both in less developed countries and in the United States. The industry has replied with economic and legal justifications for its actions. The result has been a communication gap between the industry on the one hand and poor nations and American critics on the other. This paper attempts to present and evaluate the arguments on all sides and suggests a possible way out of the current impasse. It attempts to determine the ethical responsibility of the drug industry in making drugs available to the needy, while at the same time developing the parallel responsibilities of individuals, governments, and NGOs. It concludes with the suggestion that the industry develop an international code for its self-regulation
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
Pepe Lee Chang (2006). Who's in the Business of Saving Lives? Journal of Medicine and Philosophy 31 (5):465 – 482.
Janet Malek (2006). Introduction. Journal of Medicine and Philosophy 31 (5):441 – 446.
Similar books and articles
Shaili Jain (2007). Understanding Physician-Pharmaceutical Industry Interactions. Cambridge University Press.
Włodzimierz Kubiak (2005). Medicine and Pharmacy — Facts and Myths About the Development of an Innovative Pharmaceutical Industry in Poland. Science and Engineering Ethics 11 (1):41-51.
Edward R. Balotsky (2009). Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries. [REVIEW] Journal of Business Ethics 84 (1):75 - 88.
Harvey E. Bale (2005). Industry, Innovation and Social Values. Science and Engineering Ethics 11 (1):31-40.
Nicole Hassoun (2012). Global Health Impact: A Basis for Labeling and Licensing Campaigns? Developing World Bioethics 12 (3):121-134.
Rivka Amado & Nevin M. Gewertz (2004). Intellectual Property and the Pharmaceutical Industry: A Moral Crossroads Between Health and Property. [REVIEW] Journal of Business Ethics 55 (3):295 - 308.
Joao Calinas-Correia (2013). Big Pharma: A Story of Success in a Market Economy. [REVIEW] Medicine, Health Care and Philosophy 16 (2):305-309.
Anand Grover, Brian Citro, Mihir Mankad & Fiona Lander (2012). Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability Under the Right to Health. Journal of Law, Medicine and Ethics 40 (2):234-250.
Nevin M. Gewertz & Rivka Amado (2004). Intellectual Property and the Pharmaceutical Industry: A Moral Crossroads Between Health and Property. [REVIEW] Journal of Business Ethics 55 (3):295 - 308.
David Barnard (2002). In the High Court of South Africa, Case No. 4138/98: The Global Politics of Access to Low-Cost AIDS Drugs in Poor Countries. [REVIEW] Kennedy Institute of Ethics Journal 12 (2):159-174.
Michael Gorman (2005). Intellectual Property Rights, Moral Imagination, and Access to Life-Enhancing Drugs. Business Ethics Quarterly 15 (4):595-613.
Added to index2011-01-09
Total downloads16 ( #101,113 of 1,098,880 )
Recent downloads (6 months)4 ( #79,596 of 1,098,880 )
How can I increase my downloads?